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Wang et al. show that K98 acetylation of
mouse p53 by CBP further contributes to
the regulation of p53 transcriptional
function by other known p53 acetylations
(K117/161/162). Simultaneous absence of
acetylation at K98 and at other positions
in the DNA-binding domain results in the
loss of tumor suppression in xenografts
and ferroptosis.
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Although previous studies indicate that loss of p53-
mediated cell cycle arrest, apoptosis, and senes-
cence does not completely abrogate its tumor
suppression function, it is unclear how the remaining
activities of p53 are regulated. Here, we have identi-
fied an acetylation site at lysine K98 in mouse p53 (or
K101 for human p53). Whereas the loss of K98 acet-
ylation (p53K98R) alone has very modest effects on
p53-mediated transactivation, simultaneous muta-
tions at all four acetylation sites (p534KR: K98R+
3KR[K117R+K161R+K162R]) completely abolish its
ability to regulate metabolic targets, such as TIGAR
and SLC7A11. Notably, in contrast to p533KR,
p534KR is severely defective in suppressing tumor
growth in mouse xenograft models. Moreover,
p534KR is still capable of inducing the p53-Mdm2
feedback loop, but p53-dependent ferroptotic re-
sponses are markedly abrogated. Together, these
data indicate the critical role of p53 acetylation in fer-
roptotic responses and its remaining tumor suppres-
sion activity.INTRODUCTION
The p53 protein has been well characterized for its response to
various cellular stresses, including induction of growth arrest,
senescence, and apoptosis. Recently, however, roles of p53
have expanded beyond the canonical function of apoptosis
and cell growth arrest and now include cellular processes,
such as metabolism, oxidative balance, aging, autophagy, and
ferroptosis (Feng et al., 2011; Jiang et al., 2015a; Levine and
Oren, 2009; Vousden and Prives, 2009). Because of the extraor-
dinary diversity of p53 functions, many have postulated that
mechanisms exist to allow p53 to selectively activate down-
stream targets in specific functional groups, depending on the
cellular context.366 Cell Reports 17, 366–373, October 4, 2016 ª 2016 The Authors.
This is an open access article under the CC BY-NC-ND license (http://p53 activity is regulated by a complex network of fine-tuning
mechanisms that include p53 protein stability, co-activator and
inhibitor recruitment, and a diverse array of post-translational
modifications, including acetylation, ubiquitination, phosphory-
lation, methylation, sumoylation, and neddylation (Eischen and
Lozano, 2014; Gannon and Jones, 2012; Kruse and Gu, 2009).
Specifically, acetylation of p53 has been established to play a
major role in controlling promoter-specific activation of down-
stream targets during stress responses. Previous studies have
demonstrated that acetylation at K120 by Tip60/MOF is impor-
tant for p53-mediated apoptosis (Sykes et al., 2006; Tang
et al., 2006), whereas acetylation at K164 by CBP/p300, along
with K120 acetylation, contributes to p53-induced cell cycle
arrest (Tang et al., 2008). More recently, the p533KR mouse
model that expresses acetylation-deficient p53 (K117/161/
162R), which mirrors the K120/164R mutations in human p53,
demonstrated that, whereas apoptotic and growth arrest func-
tions of p53 are lost, p53-dependent metabolic regulation is still
intact (Li et al., 2012).
Although the molecular mechanism of how p53 achieves tu-
mor suppression is not entirely understood, it has long been
accepted that tumor proliferation can be inhibited by p53-medi-
ated apoptosis, cell growth arrest, and senescence. However,
several mouse models suggest that tumor suppression by p53
can be achieved in the absence of those canonical functions.
Analysis of the p21/WAF1 knockout mice revealed no evidence
of spontaneous tumorigenesis in the absence of growth arrest
(Choudhury et al., 2007). Similarly, studies on apoptosis-defi-
cient Puma and Noxa double knockout mice also failed to
observe any increased tendency in tumor formation (Michalak
et al., 2008). More strikingly, the p533KR acetylation-deficient
and the p5325,26 TAD mutant mouse models, both of which
lack the ability to undergo p53-mediated apoptosis and cell
cycle arrest, are not significantly prone to developing tumors
when compared to wild-type mice (Brady et al., 2011; Li et al.,
2012). Data from the p21/puma/noxa/ triple knockout
mice further validated the notion that apoptosis and growth ar-
rest are dispensable for tumor suppression (Valente et al.,
2013). Furthermore, our most-recent study showed that,
whereas p533KR cannot elicit cellular apoptosis, it retains the
ability to promote ferroptosis, an iron-dependent alternativecreativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Acetylation of Human p53 at K101
and Mouse K98 by CBP
(A) Cartoon figure depicting the K101 lysine residue
(K98 for mouse p53) located in the N-terminal end of
the DNA-binding domain.
(B) Mass spectrometry of purified p53 protein in the
presence of CBP uncovered acetylation of p53 at
the K101 lysine residue.
(C) H1299 cells were transfected with vectors ex-
pressing either Flag-tagged human wild-type or
K101R mutant p53 in the presence of CBP and
Tip60. Whole-cell lysates were collected, and Flag-
tagged p53 was immunoprecipitated using M2 Flag
beads. K101-acetylated p53 was detected using
site-specific antibody. See also Figures S1 and S3A.
(D) H1299 cells were transfected with vectors ex-
pressing Flag-tagged human wild-type p53 and
various acetyltransferases (CBP, PCAF, MOF, and
Mec17). Similar to (C), site-specific acetylation
antibody against AcK101-p53 was used to detect
presence of K101 p53 acetylation after immuno-
precipitation of p53. See also Figure S2.
(E) Similar experiment to (C) was performed using
Flag-taggedmousewild-type or K98Rmutant p53 in
the presence of CBP, and p53 acetylation at K98
was detected using the same site-specific antibody
against acetylated K101.
(F) HCT116 cells were treated with 10 nM actinomycin D for 0, 8, and 24 hr. K101-acetylated p53 was immunoprecipitated using site-specific antibody from
whole-cell lysates, and the immunoprecipitation (IP) products were detected using DO-1 (p53) antibody. See also Figure S3B.
(G) Similar experiment to (F) was performed using 20 mM etoposide and 0.2 mg/mL doxorubicin treatments for 0, 12, and 24 hr.cell death pathway, whichmay constitute a potential mechanism
of p53-mediated tumor suppression (Jiang et al., 2015a).
To further elucidate the mechanism of p53 regulation, we con-
ducted a mass spectrometry screening to uncover previously
unknown modifications of p53. Here, we identified a p53 acety-
lation site at lysine K101 within the DNA-binding domain. Lysine
residue K101 of p53 is evolutionarily conserved and has been
found to be mutated in human cancers. In this study, we demon-
strated that K101 in human p53, as well as the homologous K98
lysine residue inmouse p53, can be acetylated by acetyltransfer-
ase CBP. Acetylation at this site does not contribute to p53 sta-
bility or DNA-binding capabilities. Ablation of K98 acetylation in
mouse p53 alone only resulted in a modest decrease in the tran-
scriptional activity of p53. However, simultaneous loss of K98
acetylation (p534KR98) with the previously characterized K117/
161/162 acetylations (p533KR) significantly abrogates p53-medi-
ated transcriptional regulation of its metabolic targets, including
TIGAR, GLS2, and SLC7A11. Interestingly, p534KR98 is unable
to induce ferroptosis, and its ability to thwart cancer growth is
also abrogated. Thus, our studies have significant implication
regarding the role of acetylation in regulating p53-mediated fer-
roptosis and tumor suppression.
RESULTS
p53 Is Acetylated at the K98 Lysine Residue by CBP
To screen for unidentified acetylation of p53, we purified and
analyzed ectopically expressed p53 protein in H1299 cells in
the presence of different histone acetyltransferases by mass
spectrometry. To increase the yield of acetylated forms of p53,
we treated the cells with deacetylases inhibitors trichostatin A(TSA) and nicotinamide for 8 hr before isolating the acetylated
p53. Our mass spectrometry data showed that, in the presence
of acetyltransferase CBP, p53 is found to be acetylated at lysine
residue K101, a previously uncharacterized p53 modification
(Figures 1A and 1B). CBP is a histone acetyltransferase that
also acetylates p53 at K164 in the DNA-binding domain (Tang
et al., 2008). The K101 lysine residue resides in the DNA-binding
domain of p53 and is homologous to the K98 lysine residue in
mouse p53 (Figure 1A). Interestingly, the K101 lysine residue ap-
pears to be evolutionarily conserved (Figure 1B).
To validate the acetylation at K101, we generated a rabbit
monoclonal antibody specifically against p53 acetylated at
lysine K101. We first confirmed p53 acetylation by CBP by trans-
fecting H1299 p53-null cells with vectors expressing either Flag-
tagged wild-type p53 or K101R p53 in the absence or presence
of acetyltransferase CBP, and the tagged p53 were immunopre-
cipitated and resolved on SDS-PAGE for western blot analysis.
The site-specific AcK101-p53 antibody only recognized wild-
type p53 acetylated by CBP, but not acetylation-deficient
K101R p53 mutant (Figure 1C, lanes 1–4), which confirmed the
mass spectrometry data that CBP indeed catalyzes the acetyla-
tion of p53 at K101. In vitro acetylation assay using purified p53
and CBP proteins further validated our in vivo findings (Fig-
ure S1). Interestingly, Tip60, an acetyltransferase that acetylates
p53 at K120 lysine residue in the DNA-binding domain, does not
acetylate p53 at K101 (Figure 1C, lanes 5 and 6). Furthermore,
co-transfection of vectors expressing other acetyltransferases
(PCAF, MOF, and Mec17) with p53-expressing vectors did not
result in K101 acetylation of p53 (Figure 1D). However, given
its structural similarity to CBP, p300 is able to acetylate p53 at
the K101 lysine residue as well, albeit with significantly lowerCell Reports 17, 366–373, October 4, 2016 367
Figure 2. Effect of K98 Acetylation on the
Activation of TIGAR Gene, p53 Stability, and
DNA Binding Capacity
(A) H1299 cells were transfected with empty vector
and vectors expressing wild-type and various KR
mutant p53. Expressions of TIGAR and p21 were
detected via western blotting.
(B) H1299-inducible p53 stable lines expressing
wild-type, 3KR, or 4KR98 p53 were treated with
5 mg/mL doxycycline for 0, 12, 24, and 36 hr to
induce p53 expression. Expressions of p53 targets
were detected via western blotting using TIGAR,
PUMA, and p21 antibodies.
(C) Cells were treated similar to (B), total RNA was
extracted and reverse transcribed to cDNA, and
qPCR was performed to measure TIGAR mRNA
levels. Bar graph depicts mean ± SEM of three
separate experiments. See also Figure S4.
(D) H1299 cells were transfected with TIGAR lucif-
erase construct along with increasing amount of
plasmids expressing wild-type, 3KR, or 4KR98 p53.
Cell lysates were collected and assayed for lucif-
erase activity. Bar graph depicts mean ± SEM of
three separate experiments.
(E and F) H1299 cells were transfected with vectors
expressing either (E) human p53 or (F) mouse p53 in
the presence of increasing amount of MDM2-ex-
pressing plasmid. The levels of MDM2 and p53 proteins were determined via western blotting using MDM2 and DO-1 (human p53) or CM5 (mouse p53)
antibodies.
(G) ChIP assay was performed on Tet-on-inducible H1299 cells that were treated with doxycycline to induce p53 expression for 8 hr. The immunoprecipitated
DNA was amplified by PCR using primers that span the p53-binding region on TIGAR promoter, and the PCR products were resolved on agarose gel.efficiency (Figure S2). A similar experiment was performed using
mouse p53, and the AcK101-p53 antibody also recognized acet-
ylation of mouse p53 at K98 in the presence of CBP (Figure 1E).
Moreover, we further validated the specificity of the AcK101-p53
antibody against p53 with acetylated K101 residue by demon-
strating the inability of the antibody to immunoprecipitate the
acetylation-deficient p53K101R mutant (Figure S3A).
Next, we wish to investigate whether p53 acetylation at K101
occurs endogenously. AcK101-p53 antibody was used to immu-
noprecipitate the K101-acetylated form of p53 in HCT116 cells
after DNA damage, and the levels of AcK101-p53 were detected
using anti-p53 DO-1 antibody. As seen in Figures 1F and 1G, the
steady-state levels of AcK101-p53 increased as p53 became
stabilized after drug treatments. Knockdown of CBP in
HCT116 cells significantly diminished the level of K101 acetyla-
tion after DNA damage, although trace amount of acetylation
can still be detected, likely due to overlapping acetyltransferase
activities from p300 (Figure S3B; also see Figure S2). Together,
our results indicate that K101 lysine residue of p53 is a bona
fide acetylation site of CBP both in vitro and in vivo.
Simultaneous Mutations at K117/161/162 and K98
Impair p53 Transcriptional Activities
Previous studies have shown that p533KR with triple lysine-to-
arginine mutations K117/161/162R retains regulation on Mdm2
and certain metabolic targets (Li et al., 2012). In light of this,
we wish to investigate whether ablation of K98 acetylation would
further impair mouse p53 transcriptional activities. Ectopic
expression of mouse p53K98R in H1299 p53-null cells showed
that the transcriptional activity of this single-mutation p53 was368 Cell Reports 17, 366–373, October 4, 2016comparable to wild-type p53, with only a subtle decrease in
p21 and TIGAR transactivation. However, when simultaneously
mutating lysine residues at K117/161/162 and K98, the resulting
mouse p534KR98 mutant exhibits significant defect in transacti-
vating TIGAR expression (Figure 2A). To characterize the dy-
namics of downstream target expression in amore-physiological
manner, Tet-on-inducible H1299 stable lines conditionally ex-
pressing wild-type mouse p53 and various mouse p53 mutants
were generated. Induction of wild-type p53 and p533KR expres-
sion by doxycycline treatment led to increased expression of
TIGAR, whereas induction of the p534KR98 mutant failed to do
so (Figure 2B). These findings demonstrate that ablation of the
K98 acetylation alone does not significantly affect mouse p53
activity, suggesting functional redundancy through other acety-
lations (such as acetylations at K117/161/162). However, dis-
rupting all four acetylation sites exhibits significant defect in
p53 transcriptional activity, which indicates that, in the absence
of K117/161/162 acetylations, K98 acetylation may be critical for
p53-mediated regulation on certain targets.
To confirm that the defect in activating downstream targets by
p534KR98 is transcriptional in nature, we quantified the mRNA
levels of TIGAR after p53 induction in Tet-on-inducible stable
lines. Indeed, induction of wild-type mouse p53 and p533KR
enhanced TIGAR mRNA expression, whereas induction of
p534KR98 failed to do so (Figure 2C). Similarly, co-transfection
of TIGAR luciferase reporter construct with vector expressing
the p534KR98 mutant in H1299 p53-null cells resulted in dimin-
ished reporter activity, compared to transfection of vectors ex-
pressing wild-type mouse p53 and p533KR mutant (Figure 2D).
In addition, consistent with our previous data, transcriptional
Figure 3. Effect of K98 Acetylation on Tumorigenicity
(A) Xenograft tumors obtained from Tet-on p53 3KR and 4KR98 cells that were
injected into the flanks of Nude mice.
(B) Tumor weights were determined (mean ± SEM from four tumors). Inde-
pendent experiments were repeated two times, and representative data are
shown.
(C and D) SLC7A11 levels in tumor tissues were determined by (C) protein
expression via western blot and (D) mRNA quantification via qPCR analysis
(mean ± SEM from four tumors).regulation on GLS2 is retained by p533KR, but not by p534KR98
(Figure S4).
Acetylation in the DNA-Binding Domain Does Not Affect
p53 Stability or DNA Binding
One of the functions of p53 acetylation is to increase p53 stability
by competing against ubiquitination on lysine residues. There-
fore, we wish to examine whether or not mouse K98 and other
acetylation sites in the DNA-binding domain affect p53 stability.
We observed that, in the presence of human MDM2, wild-type
mouse p53 and the lysine-to-arginine mouse p53 mutants are
degraded to a similar degree (Figure 2E). Similar results were ob-
tained using human p53, suggesting that acetylations in the
DNA-binding domain do not affect p53 stability (Figure 2F).
Acetylation in the DNA-binding domain also raises the ques-
tion of whether these acetylations alter the affinity of p53 to
DNA. To assess the DNA-binding capabilities of mouse p53
with different acetylation potentials, we performed chromatin
immunoprecipitation (ChIP) using wild-type and various acetyla-
tion-deficient mouse p53. After doxycycline-induced p53
expression in the Tet-on-inducible cell lines, wild-type mouse
p53 and p533KR/p534KR98 mutants were all able to recruit to
the TIGAR gene promoter, albeit with a slight reduction in bind-
ing affinity with the p534KR98 mutant (Figure 2G). However, the
TIGAR expression is completely abrogated in the presence of
the p534KR98 mutant (Figures 2A–2C), suggesting that its mildeffect on DNA binding could not account for the transcriptional
defect observed. These data indicate that the acetylation in the
DNA-binding domain does not dramatically affect p53 stability
or DNA binding to exert control on p53 transcriptional function.
Loss of K98 Acetylation Impairs the Tumor-Suppressive
Function of p53
As clearly demonstrated by the p533KR knockin mice, tumor-
suppressive activity of p533KR is largely preserved. Although
p533KR maintains its transcriptional regulation on a subset of
p53-mediated targets, which include MDM2 and several meta-
bolic genes (i.e., TIGAR and GLS2), the downstream effector(s)
that confer the observed tumor suppression by p533KR is still un-
known. Whereas metabolic targets, such as TIGAR and GLS2,
are postulated to play a role in p53-mediated tumor suppression,
they may have dual opposing roles of preventing cancerous
metabolic alterations on the one hand and tumor survival on
the other (Wang and Gu, 2014). Nevertheless, we decided to
investigate whether or not K98 acetylation would contribute to
the tumor suppressor function of p53. To test this, we performed
xenograft assays by injecting Tet-inducible p53-null H1299 cells
expressing p533KR or p534KR98 in Nu/Nu Nude mice (Charles
River Laboratories). Upon tetracycline induction of p533KR, the
growth of injected H1299 cells was significantly diminished
in the xenograft assays; surprisingly, however, induction of
p534KR98 in H1299 cells resulted in no reduction of xenograft
growth (Figures 3A and 3B).
Even though our data demonstrated that TIGAR expression is
lost in p534KR98, recent study with Tigar-knockout mice sug-
gested that TIGAR function actually promotes efficient tumori-
genesis through reactive oxygen species (ROS) regulation
(Cheung et al., 2013) and therefore is unlikely to contribute to
the loss of tumor suppression in p534KR98. Because our lab
has recently linked SLC7A11-dependent ferroptosis to p53-
mediated tumor suppression (Jiang et al., 2015a), we decided
to investigate the expression of SLC7A11 in the xenograft tu-
mors. SLC7A11 plays a crucial role in cystine uptake that subse-
quently prevents ferroptosis, and downregulation of SLC7A11
expression through transcriptional regulation by p53 can induce
this iron-dependent cell death process independently from
apoptosis and therefore represents a potentially significant
conduit that exerts p53-mediated tumor suppression. As ex-
pected, induction of p533KR repressed the levels of SLC7A11
protein andmRNA in xenograft tumors; however, to our surprise,
SLC7A11 expression in xenografts remained robust in the pres-
ence of p534KR98 activation (Figures 3C and 3D).
Regulation of SLC7A11 Gene Expression and
Ferroptosis Response Is Retained by p533KR but Lost in
p534KR98
We further validated the effect of K98 acetylation on the regula-
tion of SLC7A11 gene using H1299 Tet-on-inducible cell lines.
As consistent with the xenograft data, the protein levels of
SLC7A11 were significantly reduced in the presence of wild-
type p53 and p533KR, whereas no effect on SLC7A11 expression
was observed with p534KR98 protein expression (Figure 4A). Pro-
tein levels of p21, PUMA, TIGAR, and MDM2 reflect the
observed transcriptional function of the respective wild-typeCell Reports 17, 366–373, October 4, 2016 369
Figure 4. Regulation of SLC7A11 Gene Expression and p53-Dependent Ferroptosis Are Retained by p533KR, but Not by p534KR98
(A) Tet-on-inducible H1299 cell lines were induced with doxycycline for the length of times indicated, and crude cell lysates were obtained for western blot
analysis using antibodies against SLC7A11, MDM2, TIGAR, PUMA, p21, p53, and actin.
(B) Total RNA was extracted from Tet-on-inducible H1299 cell lines that were either not induced or induced with doxycycline for 24 hr. qPCR was performed to
measure the mRNA levels of SLC7A11. Bar graph depicts mean ± SEM of three separate experiments.
(C) Expression profile of Tet-on-inducible H1299 cell lines expressing wild-type and K98R p53 was analyzed similar to (A).
(D) ChIP assay was performed on Tet-on-inducible H1299 cells conditionally expressing 3KR and 4KR98 p53 that were treated with doxycycline to induce p53
expression for 8 hr. The immunoprecipitated DNA was amplified by PCR using primers on SLC7A11 and CDKN1A (p21) promoters, and the PCR products were
resolved on agarose gel.
(E) Tet-on-inducible H1299 cells conditionally expressing 3KR or 4KR98 p53were treatedwith doxycycline, erastin, or doxycycline + erastin for 48 hr, at which cell
death was observed.
(F) The relative number of live and dead cells was counted for (E), and the graph depicts the mean ± SEM of three separate experiments.
(G) Tet-inducible H1299 cells expressing 4KR98 p53 were subjected to either mock or SLC7A11 depletion via small interfering RNA (siRNA) for 48 hr and were
either left untreated or subsequently treatedwith doxycycline, erastin, or both for 36 hr. Cell countingwas donewith trypan blue via hemocytometer. Percent dead
cells was calculated and reported in the bar graph, which depicts the mean ± SEM of three separate experiments.
See also Figure S5.and mutant p53. Similarly, mRNA expression of SLC7A11 upon
wild-type p53 and p533KR induction both reduced to 40% of
baseline, whereas its expression after p534KR98 induction re-
mained unchanged (Figure 4B). As expected, repression of
SLC7A11 expression level was only minimally affected by the
absence of K98 acetylation (Figure 4C). Interestingly, although
p534KR98 mutant has lost its ability to repress SLC7A11 expres-
sion, it still retains its ability to bind to the SLC7A11 promoter
(Figure 4D).
SLC7A11 gene codes for a subunit of the cystine/glutamate
antiporter (system xc
), which antagonizes one of the pathways
that leads to ferroptosis. This process is inhibited by erastin, an370 Cell Reports 17, 366–373, October 4, 2016inhibitor of system xc
, and consequently promotes ferroptosis
through upstream blockade of cystine uptake (Dixon et al.,
2012). H1299 cells, like many other cancer cells, have elevated
levels of SLC7A11 expression and therefore are resistant to era-
stin-induced ferroptosis in the absence of p53 induction (Fig-
ure 4E, third panel from the left). However, in the presence of
p533KR expression after doxycycline induction, repression of
SLC7A11 expression by p53 sensitized cells to undergo era-
stin-induced ferroptosis, whereas p534KR98 induction failed to
do so (Figure 4E, right-most panel). Quantification of cell death
and survival is shown in Figure 4F.Moreover, SLC7A11 depletion
in Tet-inducible H1299 cells expressing p534KR98 reversed the
ferroptotic-resistant phenotype of p534KR98-expressing cells
after erastin treatment (Figures 4G, S5A, and S5B). A recent
study has also implicated GLS2, a known p53 metabolic target,
as an inducer of ferroptotic cell death by way of promoting glu-
taminolysis (Gao et al., 2015). As shown earlier, p534KR98 also
failed to induce GLS2 expression, whereas p533KR still retained
regulation on GLS2 (consistent with our prior study) and thus
may also contribute to the inability of p534KR98 to elicit ferroptotic
response (Figure S4). Together, these results indicate that K98
acetylation of mouse p53 plays a critical role in the repression
of SLC7A11 gene expression and p53-mediated ferroptosis,
which may contribute to the observed suppression of tumor
growth in our xenograft model.
DISCUSSION
The role of p53 acetylation can be thought of as a ‘‘code’’ that
dictates the functional purpose of p53 by allowing a specific
subset of downstream targets to be regulated by the p53 com-
plex that possesses the corresponding code, which is repre-
sented by the combination of the acetylated lysine residues.
We observed that ablation of acetylation at K98 in mouse p53
alone did not affect transcriptional activity of p53. Interestingly,
when simultaneously disrupting acetylations at K117/161/162
and K98, transactivation of TIGAR gene and repression of
SLC7A11/Slc7a11 gene, which are retained by p533KR, were
compromised. Collectively with previous findings, our data sug-
gest that the acetylations in the DNA-binding domain of p53 may
have redundant roles in promoter-specific regulation of p53
metabolic targets, such as TIGAR and SLC7A11/Slc7a11. In
other words, the acetylation codes for regulating p53 metabolic
targets are many and complex in nature; various acetylation sta-
tuses of p53 could permit such regulatory capacity, although it is
unclear whether there are differences in the effectiveness of
each acetylation code or disparity in the degree and context of
occurrences for each acetylation code. In mark contrast, the
p53 acetylation code for apoptotic activation via Puma/Noxa/
Bax is unique, as it simply requires site-specific acetylation at
K117, and loss of K117 acetylation completely abrogates p53-
mediated apoptotic response (Li et al., 2012). The acetylation
requirement for p53-mediated growth arrest lies somewhere in
between metabolic and apoptotic regulation, in which acetyla-
tion at either K117 or K161/162 is sufficient to elicit p21
activation and resulting G1/S-phase arrest (Li et al., 2012). Inter-
estingly, our data indicate that p53 regulation onMDM2 appears
to be retained by p534KR98, suggesting that there is even a lesser
p53 post-translational requirement for MDM2 regulation.
Whereas it is unclear how the upstream signaling pathways
and mechanics lead to specific p53 acetylations to bring about
the desired p53 function in any given cellular context, it is evident
that the regulation and manipulation of p53 acetylation has sig-
nificant biological consequences (Mellert and McMahon, 2009;
Zhang et al., 2012a, 2012b). Nevertheless, our current under-
standing of differential regulation through acetylation poses
interesting speculation of its biological purpose. In the absence
of cellular stress, K98 acetylation in mouse p53may be sufficient
for p53-mediated regulation of genes, such as Tigar or Slc7a11.
Functionally, expression of TIGAR under non-stressed conditionis appropriate, as TIGAR activity may contribute to normal
cellular energy and ROS homeostasis. Because K98 acetylation
is not sufficient to induce growth arrest and apoptotic targets, it
is a harmless form of p53 activation that can occur in the
absence of stress. Repression of SLC7A11 expression alone
via p53 is also non-toxic, as expression of p533KR in cell lines,
mouse embryonic fibroblast (MEF) cells, or in mice does not
trigger ferroptosis. Induction of ferroptosis requires additional
cellular insults (i.e., ROS stress or erastin exposure) in the setting
of p53-mediated SLC7A11 repression (Jiang et al., 2015a,
2015b). As such, downregulation of SLC7A11 under basal p53
regulation or low stress condition may provide another layer of
protection against tumorigenesis by decreasing the threshold
in which cells can tolerate ROS stress and allowing activation
of programmed cell death to circumvent potential harm from ge-
netic instability. As cells encounter genotoxic stress, p53 may
determine cell fate depending on the stress level (Helton and
Chen, 2007), and the decisionmakingmay be exerted by distinct
p53 acetylations. With mild stress, K161/162 lysine residues can
be acetylated to induce growth arrest (without triggering
apoptosis) via p21 activation, which allows cells to repair and
recover from cellular damage. However, in the face of severe
stress that causes irreparable cellular damage, mouse p53 acet-
ylation at K117 will prompt an apoptotic response through
expression of PUMA/NOXA/BAX, leading to self-elimination to
prevent the potential propagation of deleterious mutations. All
the while, regulation of MDM2, a key moderator of the highly dy-
namic p53, prevails in the absence of all the above-mentioned
acetylations, underscoring the indispensable role of the nega-
tive-feedback loop for maintaining a functional p53 axis.
Even though the acetylation sites in the DNA-binding domain
play crucial roles in p53 activation and differential regulation,
our data suggest that they do not appear to significantly affect
promoter-specific binding. For example, we observed that
wild-type p53, p533KR, and p534KR98 can all bind TIGAR gene
promoter, yet these p53 with varying capacity in acetylation
possess drastically different transcriptional activity on TIGAR.
One possibility is that the acetylations in the DNA-binding
domain alter the conformation of the p53 and in turn influence
co-activator or transcriptional machinery recruitment instead of
affecting DNA binding. Co-activators, usually histone acetyl-
transferases (such as CBP/p300, PCAF, GCN5, and Tip60), are
recruited by transcription factors to acetylate histones and
relieve the coiling of chromatin to allow transcription to occur.
Thus, it is possible that different acetylations or combinations
of acetylations may present as a form of code for association
with various co-activators and therefore allow different p53 tar-
gets to be expressed depending on the co-activator present.
Testing whether different co-activators are recruited based on
the presence of p53modifications in a promoter-specificmanner
could shed light on the mechanism behind differential regulation
by p53.
It is interesting to note that, even though there are documented
mutations of the K101 lysine residue in human cancer, the prev-
alence is low. Per the International Agency for Research on
Cancer (IARC) TP53 database for human p53 somatic mutations
(n = 24,320), there are only eight mutations documented for
K101, compared to 1,324 mutations for the R175 hotspot thatCell Reports 17, 366–373, October 4, 2016 371
completely abolish p53 transcriptional function (http://p53.iarc.
fr/). Given the implications derived from our study, this does
not come as a surprise, as mutation of the homologous K98
lysine residue alone in murine p53 did not result in significant
functional impairment. Only in the absence of other acetylations
in the DNA-binding domain does the status of K98 acetylation
become of paramount importance. Nevertheless, our study un-
derscores the mechanistic significance of p53 acetylation in ex-
erting tumor suppression and sheds light on the long-standing
question of how p53 may intelligently control a vast multitude
of targets as a master regulator.
The p533KR mouse model, as well as evidence from several
other studies, has demonstrated that p53 can still suppress tu-
mor formation in the absence of its apoptotic and growth arrest
functions (Brady et al., 2011; Li et al., 2012; Valente et al., 2013).
Preservation of p53-mediated metabolic and non-canonical
target regulation in the p533KR mouse model appears to
contribute to tumor suppression, which no longer comes as a
surprise, given the plethora of metabolic functions regulated by
p53 (Liu et al., 2015; Maddocks and Vousden, 2011). Repression
of SLC7A11 by wild-type p53 and p533KR was recently impli-
cated in p53-mediated ferroptotic cell death and subsequent tu-
mor suppression (Jiang et al., 2015a). A further loss of K98
acetylation on mouse p53, in addition to the loss of other acety-
lation events, disrupted its regulation on SLC7A11, therefore
abrogating its ability to induce ferroptosis. A recent report char-
acterizing a tumor-prone S47 p53mutant showed that themajor-
ity of the downstream effectors that were compromised by the
single amino acid mutation are involved in ferroptosis and meta-
bolism, thus further corroborating our findings that ferroptosis
may be inextricably linked to p53-mediated tumor suppression
(Jennis et al., 2016).
Loss of TIGAR regulation with p534KR98 may also theoretically
contribute to impairment of p53-mediated tumor suppression,
although functional study of TIGAR-knockout mice suggests a
tumor pro-survival role for the TIGAR gene (Cheung et al.,
2013). There may also be other p53 targets (identified or yet un-
known) regulated by p533KR, of which regulation is compromised
in the absence of K98 acetylation, that played a part in the dy-
namics of tumor suppression observed in our study. In conclu-
sion, we have identified a mouse p53 acetylation at K98 lysine
(K101 for human p53) that is crucial for the regulation of p53
metabolic targets, and the loss of K98 acetylation in the absence
of other critical acetylations in the DNA domain resulted in the
failure of p53 to mediate ferroptosis and effectively suppress tu-
mor growth through these targets.EXPERIMENTAL PROCEDURES
Protein Purification and Mass Spectrometry
To purify the acetylated p53 protein for mass spectrometric analysis, H1299
cells were co-transfected with CMV-Flag-p53 and CMV-CBP-HA, cultured
for 16 hr, and then treated with 1 mM TSA + 5 mM nicotinamide for 8 hr. Cells
were harvested and lysed in the Flag-lysis buffer (50 mM Tris-HCl [pH 7.9],
137 mM NaCl, 10 mM NaF, 1 mM EDTA, 1% Triton X-100, 0.2% sarkosyl,
10% glycerol, and fresh proteinase inhibitor cocktail; Sigma) plus 2 mM TSA
and 10 mM nicotinamide. The cell extracts were then immunoprecipitated
with the anti-Flagmonoclonal antibody-conjugatedM2 agarose beads (Sigma)
and eluted using Flag peptide (Sigma). The eluted material was resolved by372 Cell Reports 17, 366–373, October 4, 2016SDS-PAGE on a 4%–20% Tris-glycine gradient gel (Invitrogen), and the p53
bands were excised and subjected to mass spectrometric analysis.
Cell Death Assay
For cell death assays, p53 was pre-activated for 24 hr by doxycycline in Tet-
on-inducible stable line cells, followed by treatment with or without erastin
for an additional 48 hr. Cells were approximately 40% confluent when erastin
was added to the culture. For quantification of cell death, cells were trypsinized
and stained with trypan blue, followed by counting with a hemocytometer us-
ing standard protocol. Cells stained blue were considered as dead cells.
Mouse Xenograft
H1299 Tet-on 3KR and 4KR98 stable cell lines were treated with or without
doxycycline (0.5 mg/mL) for 40 hr. Cells (1.2 3 106/100 mL) were then mixed
with Matrigel (BD Biosciences) at 1:1 ratio (volume) and injected subcutane-
ously into Nude mice (Nu/Nu; Charles River). Mice were fed either with control
food or food containing doxycycline hyclate (Harlan; 625mg/kg). Six weeks af-
ter injection, mice were euthanized and tumors were dissected from under the
skin. Maintenance and experimental procedures of micewere approved by the
Institutional Animal Care and Use Committee (IACUC) of Columbia University.
Statistical Methods
Statistical analysis was performed using Excel. Treatment samples were
compared using the two-sample Student’s t test. Data were presented as
means ± SEM. Statistical significance was defined as p < 0.05.
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